Brian Quarton, MD
Family Medicine · Gillespie, ILNPI 1417951401
Payments from drug & device makers
Across 232 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$633
- AbbVie$474
- AstraZeneca$436
- Pfizer$300
- Novartis$276
- Amgen$253
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,917100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $633 |
| AbbVie | 31 | $474 |
| AstraZeneca | 26 | $436 |
| Pfizer | 17 | $300 |
| Novartis | 18 | $276 |
| Amgen | 14 | $253 |
| Lilly USA, LLC | 9 | $179 |
| Astellas Pharma US Inc | 8 | $154 |
| Boehringer Ingelheim | 9 | $154 |
| E.r. Squibb & Sons, L.L.C. | 8 | $128 |
| Johnson & Johnson | 6 | $119 |
| Braeburn Inc. | 5 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Amarin Pharma, Inc. | 5 | $77 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Biogen | 3 | $51 |
| Viatris Specialty LLC | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $47 |
| Seqirus USA Inc | 1 | $42 |
| Lundbeck LLC | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Medtronic | 2 | $28 |
| Gilead | 2 | $24 |
| Bayer | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Indivior Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Qiagen, LLC | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,917 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 274 | $136,165 |
| JardianceEmpagliflozin | 86 | $68,984 |
| TrulicityDulaglutide | 54 | $62,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $39,986 |
| OzempicSemaglutide | 36 | $35,377 |
| MounjaroTirzepatide | 29 | $31,741 |
| XareltoRivaroxaban | 54 | $21,501 |
| MyrbetriqMirabegron | 47 | $20,396 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $18,710 |
| Metformin Er OsmoticMetformin Hcl | 12 | $15,380 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $15,179 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $13,630 |
| RybelsusSemaglutide | 15 | $13,287 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $8,755 |
| Repatha SureclickEvolocumab | 13 | $8,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $300 | $136,165274 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $179 | $93,78183 claims |
| Boehringer IngelheimJardiance, Tradjenta | $154 | $76,436104 claims |
| Novo NordiskOzempic, Rybelsus | $633 | $48,66451 claims |
| Johnson & JohnsonXarelto, Invokana | $119 | $28,10868 claims |
| Astellas Pharma US IncMyrbetriq | $154 | $20,39647 claims |
| Indivior Inc.Suboxone | $15 | $13,63026 claims |
| AstraZenecaFarxiga, Symbicort | $436 | $12,48046 claims |
| AbbVieRestasis | $474 | $5,95516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Gillespie
- Bruce WeberGillespie$509K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.